Quick Answer
Amphastar Pharmaceuticals, Inc. reported Operating Income Loss of $140.40 million for the year ending 2025.
- Amphastar Pharmaceuticals, Inc. showed a decrease of -31.7% in Operating Income Loss from 2024 to 2025.
- This data is from Amphastar Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Amphastar Pharmaceuticals, Inc.'s Operating Income Loss has grown by 452.8%.
- Historical annual values: Fiscal year 2025: $140.40 million | Fiscal year 2024: $205.42 million | Fiscal year 2023: $196.99 million | Fiscal year 2022: $107.50 million | Fiscal year 2021: $69.89 million | Fiscal year 2020: $10.95 million | Fiscal year 2019: -$39.0 thousand | Fiscal year 2018: -$8.62 million | Fiscal year 2017: -$1.27 million | Fiscal year 2016: $15.38 million | Fiscal year 2015: -$6.90 million | Fiscal year 2014: -$17.98 million | Fiscal year 2013: $17.49 million | Fiscal year 2012: $25.40 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: